Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biochem Pharma (BCHE) -- Ignore unavailable to you. Want to Upgrade?

To: JDN who wrote (631)	6/5/1999 6:36:00 PM
From: Todd D. Wiener	Read Replies (1) \| Respond to of 783

I think BCHE's problem is that unlike U.S. companies, they aren't focused on creating shareholder value. This is not uncommon with foreign companies. I also wonder what the point of the CCHE spinoff was. I read the annual report, and it makes no sense. Basically, CCHE is an operation that is part of BCHE, but it is listed as a separate entity. I could understand if BCHE were to have reduced their R&D expense by letting CCHE handle it, and it would have increased BCHE's earnings. But they didn't do that. I'm not sure why they created CCHE. The whole company seems like it needs new management, IMO. Perhaps Glaxo could buy the company and put BCHE shareholders out of their misery. Todd